The fact that the Ang-2 serum concentrations remain high even after the third cycle of chemotherapy either in NSCLC or SCLC cases may indicate that the respective angiogenic factor could serve as a considerable therapeutic target for lung cancer patients. Here, ANGPT2 is linked to lung cancer.